TD Cowen analyst Yaron Werber reiterated a Buy rating on Celldex Therapeutics (NASDAQ: CLDX).The analyst commented, "Yesterday, Celldex reported long-term ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE